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ISSCR: President’s NoteThe ISSCR: Who Are We and Where Are We Going?As I enter my term as President, I wish to thank the members of
the ISSCR for electing me, the founders of the society—espe-
cially Leonard Zon—for their energy and vision in creating the
society, and the wise and efficient administration for keeping
us on message, intact, and solvent.
We are a field, a discipline, and an entire branch of science that
brings new ideas, experiments, concepts, and approaches that
impinge on every field of biomedical research and medical trans-
lation. Like anything new, we are a threat to the established order,
and at every kind of educational and research institution, to thrive
we must be recognized as entities, not divisions of the old entities.
The Field of Stem Cell Biology and Its Relationship
to Regenerative Medicine
A stem cell is a cell that can both self-renew and differentiate to
form clones of stem, progenitor, and mature cells. This is a very
simple definition that may not, at first glance, appear to define
a field, but its application to development, tissue homeostasis,
cancer, and therapies reveals in our new discoveries a field
that was absent before. Tissue and organ stem cells are in
most cases the only self-renewing cells in those tissues and,
as such, are ultimately responsible for the lifelong homeostatic
maintenance of the tissues. They are also the only cells that
are necessary and sufficient for transplantation to regenerate
tissues: the operative cell for regeneration in bone marrow trans-
plants is the hematopoietic stem cell (HSC) and, in muscle, the
subset of satellite cells that are the muscle stem cells. Very few
tissue stem cells have been prospectively isolated, so we have
far to go to in building the field of regenerative medicine. Further-
more, once isolated, it is essential to show that the putative
tissue stem cells are clonogenic cells that both self-renew and
differentiate to form their cognate tissue. Although there are
many claims that stem cells of one tissue naturally transdifferen-
tiate to become stem cells for any other tissue to which they
migrate or are placed, it is my view that there are no credible
demonstrations of tissue stem cell transdifferentiation.
Pluripotent stem cells are clonogenic cells that can give rise to
all tissue stem cells, and thus tissues, of the body. Their exis-
tence in the body at any stage is controversial, but cultures of
pluripotent stem cells from several species allow the study of
developmental cell lineages where precursor cell and progeny
cell can be identified, isolated, and spec-
ified. One important aspect of pluripotent
stem cell biology is the ability of these
cells to pass through the various tissue
stem cell stages while making the mature
cells of the related tissues. These are the
cells that might be used, with or without
modification, to regenerate tissues in
a recipient. While the study of develop-
mental genetics reveals the role of partic-
ular genes in the development or survival
of body components, stem cell biology
and the study of clonal lineages remains
the only way to determine precursor-
progeny lineage relationships.
Aging, too, can be approached anew by the study of clonal
populations of tissue stem cells, all of which were derived for
the last time in the fetus in vertebrates, as they compete and
are selected, and perhaps matured. The clonal progressions
that occur normally in aging can go awry, and premalignant
clones of cells with altered proclivities of self-renewal and differ-
entiation develop. The progression of genetic and epigenetic
events in these clones can result in the emergence of cancer
stem cells, or tumor-initiating cells—the self-renewing cells in
a cancer that still differentiate to non-self-renewing but coexist-
ing tumor progeny. This concept and field is changing and
remains controversial. Perhaps the ultimate progression of
cancer stem cells is to cells which fail differentiation and
approach unity efficiency as tumor-initiating cells. The cancer
stem cell hypothesis will be tested finally by methods that kill
only these tumor subsets in the patient or animal of origin; if
the tumor is gone and the cancer is cured, cancer stem cells
were indeed the drivers of the malignancy.
Translation of tissue stem cells to regenerative medicine will
require either transplantation of isolated cells from a donor to
a host (or in some cases, from a patient back to self) after thera-
pies that require tissue regeneration from the isolated stem cells,
or small molecules or proteins that act in vivo to expand and/or
rejuvenate a nascent stem cell pool. These are not today tradi-
tional therapies carried out by the pharmaceutical or biotech-
nology sectors, and we will need to find ways to surmount the
many barriers to bring in a new era of regenerative medicine.
I believe it is a function of the ISSCR to be central to the changes
that must occur to usher in this era. Stem cells are the root of
regenerative medicine, and stem cells and their progenitors are
the core of cell-lineage analyses. The stem cell field deserves
and needs examples of PhD-granting programs in its subject
matter and needs to be in independent entities, not departmental
divisions. In future communications, I hope to work with ISSCR
members to establish working groups to move the field forward.
Reprogramming, Plasticity, Politics, and a Clarion Call
in the U.S. by President Obama
While transdifferentiation of one tissue stem cell type to another,
and dedifferentiation of a specialized cell to a pluripotent state,
have not convincingly been shown to
occur in vivo in vertebrates, experimental
methods to reprogram adult tissue cells
to pluripotency are among the most
exciting engines of discovery and transla-
tion in our field.
Following the work in amphibians on re-
programming adult cells in the egg, the
cloning of Dolly showed it was possible
in vertebrates. The work of Jaenisch and
others established without doubt that
adult cells of a known type could be re-
programmed to pluripotency by somatic
cell nuclear transfer (NT). If the tissue cell
that donated the nucleus had an alteredCell Stem Cell 5, 151–153, August 7, 2009 ª2009 ISSCR 151
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stem cell line derived by NT had those same alterations and could
contribute to making all tissues of the organism, and the altered
genes were faithfully used. The tissues derived from a T cell all
had only one T cell antigen receptor rearrangement, and the T
lymphocytes derived from them only expressed that receptor
protein. The tissues derived from a melanoma cancer cell all
had the inciting Ras mutation, contributed to all cell types nor-
mally, yet progressed in every animal to develop many indepen-
dent clones of melanoma or rhabdomyosarcoma. The tissue cells
derived by NT from a mouse lacking a gene required to make
functional lymphocytes all lacked the enzyme and could not
generate lymphocytes; in a demonstration of understanding
disease pathogenesis caused by the mutation and the possible
therapeutic correction of the disorder, replacement of the mutant
gene in the NT pluripotent stem cell line led to the development of
hematopoietic cells that could treat the disease. Given these
scientific advances, a National Academies’ panel, which I
chaired, voted unanimously to encourage NT research, excluding
human reproductive cloning, to move forward, overseen and
approved by societal and governmental bodies. We cautioned
that technical issues would be a major barrier, as the source of
human oocytes would be limiting with a low-efficiency tech-
nology. Nevertheless, in order to study human disease pathogen-
esis (and even practice therapeutic cloning, a biotechnology
hype), it would be important to create human disease-specific
NT pluripotent cell lines so that scientists who study the disease
would have the broadest opportunity to develop a depth of
understanding that could lead to better diagnoses and therapies.
Yet the political landscape remained unfriendly. In a famous
speech on August 9, 2001, President Bush ruled out the use of
U.S. federal funds for research using any embryonic stem cell
(ESC) line produced after this date and also research using NT
stem cell lines, however efficiently produced. President Bush
gave his full support for bills introduced by Representative Wel-
don and Senator Brownback (ultimately not passed) to crimi-
nalize human NT research and the administration and use of
any resultant treatments. In 2005, a nonbinding United Nations
resolution was put forward, calling upon member states to ban
all NT, including research. Some countries followed suit, but
others, and the state of California, have approved human NT
research, introducing medical, ethical, and institutional over-
sight, and funding the research.
In 2006 and 2007, Yamanaka and colleagues reported a gene-
based way to reprogram somatic cells from mice and humans to
pluripotency (induced pluripotent stem cells), and it is important
to see whether tissue cells from these can, like NT stem cells,
recapitulate mouse and human genetic diseases and also avoid
being tumorigenic. So there are two very promising scientifically
validated ways to achieve reprogrammed pluripotency. We do
not know yet if they are biologically equivalent to each other, to
classical ESCs, or to the blastocyst inner-cell mass cells that
are the in vivo source of ESCs. It would be a gamble to choose
one over the other.
The imposition of the funding ban for NT biology by President
Bush had no scientific basis, but reflected his deep concern that
this practice was beyond his moral scope. This view is held by
many, and as individuals we must respect their right to such
a view, as likewise, in a pluralistic democracy, we also do not152 Cell Stem Cell 5, 151–153, August 7, 2009 ª2009 ISSCRhave to abandon our own views unless they are illegal. Whether
this represented his religious beliefs, his politics, or his own
personal morality, it was a barrier to this field of research. In
March of 2009, President Obama lifted the ban and promised
that his administration would not place political or fixed ideolog-
ical barriers in either the making of scientific policy or the
appointment of federal employees or advisers in the entire scien-
tific enterprise. He repeated these principles in a speech in front
of the National Academy of Sciences in April. He called on the
National Institutes of Health (NIH) to develop guidelines for fund-
ing ESC research that were in concert with his lifting of the ban
and with his announced set of principles. Surprisingly, the NIH
draft guidelines, released for public comment, restricted the
eligibility of ESC lines for federal funding to embryos created
by IVF for reproductive purposes and in excess of this need,
continuing the funding ban on all NT-derived stem cell lines.
(The Dickey-Wicker Amendment independently prohibits federal
funding of the derivation of classical ESC lines from blastocysts,
and by extension, from NT blastocysts). Because impeccable
science has shown the worth of NT stem cell lines in revealing
disease pathogenesis, and the application to humans is tech-
nical, it is hard to reconcile the NIH action with the Obama proc-
lamation. The ISSCR has consistently endorsed research on all
forms of stem cells, including pluripotent stem cell lines derived
via IVF, NT, parthenogenesis, or gene-based reprogramming.
The ISSCR supports such stem cell research globally, where
performed under rigorous standards of research ethics
described in the 2006 ISSCR Guidelines for the Conduct of
Human Embryonic Stem Cell Research. As representatives of
the ISSCR, the board of directors urged the NIH to open discus-
sions on funding research carried out with human pluripotent
stem cell lines derived from sources other than excess reproduc-
tive IVF embryos, including SCNT embryos, if they become avail-
able and are derived within legal and local ethical guidelines. In
the final NIH guidelines, the bans remain on funding research
using already established parthenogenic and NT pluripotent
stem cell lines, however ethically obtained and however faithfully
they replicate the pathogenesis of the human diseases from
the patient nucleus donor. They do not cite a scientific reason
for the ban. I will ask approval of the executive committee, and
the society, to continue to call for a reversal of bans on funding
research on established, ethically developed human NT and par-
thenogenic pluripotent stem cell lines.
The Sad Practice of Unapproved Stem Cell ‘‘Therapies’’
Every week, I am asked whether a family should take their loved
one with an incurable disease to clinics that promise cures with
supposed stem cell therapies. Usually, the costs for such thera-
pies are in the tens of thousands of dollars. When I go to the web-
sites of the providers, usually very slick, the therapies are often
transplantation of tissue or umbilical cord stem cells for a variety
of nonhematopoietic or nonmesenchymal disorders (claiming
transdifferentiation), or even claim to be ESC therapies. I tell
those that ask that there is no scientific basis for such transdiffer-
entiation to date and no approved therapies using ESCs. If an en-
quirer is in the biomedical field, I remind him/her that there is now
a pretty good operational way to determine whether a phenom-
enon, such as transdifferentiation, is real:
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be published in a peer-reviewed journal, but that is not
enough.
(2) Several independent laboratories should have confirmed
and published in peer-reviewed journals that the findings
as first published are reproducible, but that is not enough.
(3) The principle that underlies the discovery (e.g., transdif-
ferentiation) is so robust that any way you approach the
issue, the discovery is validated, but that is not enough
when therapeutic cell therapies are the objective.
(4) The regeneration of tissues is rapid, robust, tissue-appro-
priate, and curative, not simply rare cells of uncertain
origin.
But these are not issues the lay public calling for the cures
promised can judge alone. My own advice is that they should
attempt to obtain the following from the stem cell companies
or clinics before they agree to a therapy:
(1) The provider must be able to send peer-reviewed papers
from independent practitioners that establish the therapy
as possible.
(2) The provider must send evidence of approval from an
independent committee, such as an institutional review
board (a document from the clinical entity where the
therapy is being practiced that shows the steps taken to
protect the patient and justifying the experimental or
approved therapy for their specific disease).
(3) The provider must send a document from an agency
equivalent to the Food and Drug Administration showing
the approval of the experiment or the therapy for human
subjects with their disease.I advise them that without all three, they must assume they are
receiving an unproven therapy and that the patient is in danger of
risking their life or health, of losing their money, of being away
needlessly from home, family, and friends, and of course, of
not being therapeutically improved.
Over the past 2 years, the ISSCR has taken further steps to
support the responsible translation of stem cell research to the
clinic, releasing the Guidelines for the Clinical Translation of Stem
Cells and accompanying Patient Handbook on Stem Cell Thera-
pies (www.isscr.org/clinical_trans). As President of the ISSCR, I
propose that we develop a website and occasional press alert
naming as unproven stem cell therapies where providers of so-
called ‘‘therapies’’ cannot supply to the ISSCR, within 60 days of
request, evidence of rigorous and independent scientific and
ethical review along the lines of what I recommend patients seek.
We should be aware that the entities that cannot prove safety
and efficacy are at one extreme of an unfortunate continuum that
has, at the other end, proven therapies. We must all be cautious
in our own enthusiasms and also how we define the minimum
criteria required to achieve nonlisting on the site. We will not
be a judge of approved therapies. I hope you agree with me on
this subject, and I welcome your comments on this proposal
either way.
I ask for your understanding of this long introduction to a short
presidency. I felt it was important to establish stem cell biology
as an independent field, to establish our research as central to
the development of regenerative medicine and new types of
cancer therapies, to try to summarize the politics of stem cell
policies clearly, and to find some way to keep our legitimate
efforts separable and separate from the charlatans who compro-
mise the safety of citizens in need of hope and cure and ulti-
mately the promise of the field.
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